The role of cirrhosis etiology in the development of acute kidney injury and death

Cristian Y. Sánchez-Sánchez[1],
Karina Cazarin-Chávez[1], Diego F. Abendaño-Rivera[1],
María F. Higuera-De La Tijera[1],
Daniel Santana-Vargas[2], José L. Pérez-Hernández[1]

[1] *Department of Gastroenterology and Hepatology General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico*
[2] *Research Department General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico*

Introduction and Objectives: : Patients with hepatic cirrhosis (HC) are at risk of developing acute kidney injury (AKI) due to multiple factors. The main types of AKI are hypovolemia, acute tubular necrosis (ATN), and urinary obstruction. Common causes of HC include MAFLD, alcohol consumption, viral and autoimmune diseases, which may have a different role in the risk for AKI and mortality. This study aims to assess the etiology of cirrhosis in the development of acute kidney injury (AKI) and mortality.

Materials and Patients: Retrospective, analytical, observational study of patients with CH, analyzing etiology, type of AKI, and mortality. Statistical analysis: Using the Log-Rank test, the Kaplan-Meier curve was performed considering death at 28 and 90 days to assess the mortality rate associated with etiology. The Chi-square test with Bonferroni correction was conducted to evaluate the association between etiology and type of AKI; a significance level of ≤ 0.05 was considered.

Results: A total of 201 patients with CH were included, 106 of them being male (52.73%), with an average age of 55 ± 10.4 years. Child-Pugh classification distribution was as follows: A: 25 (12.43%), B: 70 (34.82%), and C: 106 (52.73%). The average MELD-Na score was 21.8 ± 9.45 points. The cumulative mortality rate at 28 days was 18.4% (37); the comparison by etiology showed statistical significance with a Chi-square test of 13.23 (4), p=0.01. The mean survival for MAFLD was 27.7, alcohol-related was 23.8, autoimmune was 24.1, viral was 25.92, and dual etiology was 22.56, with an overall survival of 24.88. The comparison at 90 days was significant, with a Chi-square test of 10.46 (4), p=0.033, and a cumulative mortality rate of 24.4% (49). The mean survival for MAFLD was 86.82, alcohol-related was 70.02, autoimmune was 67.03, viral was 80.07, dual etiology was 66.56, and the overall survival was 74.84. Association tests between etiology and type of renal injury showed statistical significance, with a Chi-square test of 29.65 (8), p=<0.001. Differences were found between the alcohol-hypovolemic group and the non-renal injury and ATN groups.

Conclusions: Dual etiology and autoimmune factors confer higher mortality at 28 and 90 days, respectively, while alcohol consumption increases the risk of AKI due to hypovolemia.

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consent was obtained.

**Declaration of interests**

None

**Figure 1.** 28-day survival by etiology of Hepatic Cirrhosis.

Figure 2. 90-day survival by etiology of Hepatic Cirrhosis.

Evaluation of severity and survival scales in acute-on-chronic liver failure(ACLF) in a Mexican population sample.

Sandra Teutli-Carrión, Claudia L Dorantes-Nava, José L. Pérez-Hernández

Department of Gastroenterology and Hepatology, Hospital General de Mexico "Dr. Eduardo Liceaga

Introduction and Objectives: ACLF is a syndrome characterized by multiorgan failure due to acute decompensation in chronic liver disease, with high short-term mortality. Therefore, scales have been designed to predict prognosis and early mortality. Evaluation of MELD, MELD NA, MELD LACTATE, and MELD 3.0 scales for survival prediction in ACLF patients

Materials and Patients: Observational, retrospective, and analytical study, scales were calculated, and sensitivity (S) and specificity (E) were determined using CLIF-C-ACLF as reference through ROC curves. Cut-off points were established at the maximum values of S and E. Cumulative mortality percentage by Kaplan-Meier, and comparison of ACLF grades with the Long-Rank test with p<0.005.

Results: 233 patients were included, 165 (71%) males, with a mean age of 52 years ± 12.96. The etiology was alcohol-related in 158 (68%) cases. ACLF grade distribution, it was 1: 37%, 2: 41%, and 3: 22%. The MELD 3.0 showed the highest discriminatory power for ACLF grade 3, with AUC of 0.91 (95% CI:0.86-0.96), a cut-off point of 34.5, sensitivity of 86%, and specificity of 80% (Figures 1). The 2-year mortality rate was 123 (52%); 30 (35%), 51 (53%), and 42 (82%) for grades 1, 2, and 3, respectively, with a significant Log-Rank test, chi-square = 34.99, p

<0.001. The mean survival by grades was 17 months for grade 1, 13 months for grade 2, and 5 months for grade 3 (Figure 2)

Conclusions: The MELD 3.0 scale showed better performance as a tool to evaluate severity and predict short-term mortality risk in ACLF patients.

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consent was obtained.

Declaration of interests

None

Figure 1. Comparative analysis between different scales in acute on chronic liver failures (ACLF). Meldlac: Meld Lactato

Figure 2. Kaplan-Meir. Survival by grades of acute on chronic liver failure (ACLF).

https://doi.org/10.1016/j.aohep.2024.101438

BUN/creatinine ratio associated with mortality in patients with cirrhosis and acute kidney injury.

Diego F. Abendaño-Rivera[1],
Cristian Y Sánchez-Sánchez[1],
Karina Cazarin-Chávez[1], Paloma M. Diego-Salazar[1],
Daniel Santana-Vargas[2],
María F. Higuera-De La Tijera[1],
José L. Pérez-Hernández[1]

[1] *Department of Gastroenterology and Hepatology General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico*
[2] *Research Department General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico*

Introduction and Objectives: Cirrhosis is a prevalent disease worldwide, with complications such as acute kidney injury (AKI) that increase the risk of fatal outcomes. A high BUN/creatinine ratio (IBC) has been associated with mortality in other diseases Therefore, evaluating this index in patients with cirrhosis could predict mortality. To determine whether a high BUN/creatinine ratio is associated with mortality in patients with cirrhosis and AKI.

Materials and Patients: Retrospective analysis was conducted on a cohort of cirrhotic patients with and without AKI, calculating the IBC and assessing its association with mortality.

Results: A total of 201 patients with cirrhosis were included, of whom 106 were male (52.73%), with a mean age of 55 ± 10.4 years. The distribution of Child Pugh scores was as follows: A (25, 12.43%), B (70, 34.82%), and C (106, 52.73%); the mean MELD-Na score was 21.8 ± 9.45. The cumulative mortality rate at 28 days was 37 (18.4%) and at 90 days was 39 (24.4%). The model was not significant at 28 days but was significant at 90 days with a $X2$ value of 48.18 (2) and p<0.001.

At 90 days, the model was significant with a $x2$ value of 49.7 (2) and p<0.001, with an OR (IBC) of 2.78 (1.08-7.11, 95% CI, p=0.33), and for AKI OR of 7.97 (2.2-28.8, 95% CI, p=0.02) (Figure 1). Considering either factor present, the model was significant at 28 days with a $X2$ of 27.75 (1) and p<0.001, with an OR of 7.2 (3-17.3, p<0.001), and at 90 days with a $X2$ of 35.59 (1) and p<0.001, with an OR of 6.67 (3.23-13.76, p<0.001).

Conclusions: The Cox proportional hazards model was used to compare factors associated with mortality separately for AKI (present vs. absent) and IBC (>20 mg/dl vs. <20 mg/dl) at 28 and 90 days, as well as if both factors were present. The model was considered significant if the p-value was less than 0.5. The study concluded that a higher IBC (>20 mg/dl) could predict mortality in patients with cirrhosis, as the odds ratios at 28 and 90 days were significant.

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consent was obtained.

Declaration of interests

None

Figure 1. IBC and AKI at 90 days associated with mortality.

https://doi.org/10.1016/j.aohep.2024.101439

Evaluation of the ALBI, MELD, MELD-Na, MELD 3.0 score in patients with hepatocellular carcinoma treated with Yttrium-90 (90y)

Stefanny Cornejo-Hernandez[1],
Mayra C. Galena-Hernández[2],
Blanca Zapote-Hernández[3], Itzia Verduzco-Flores[3],
Salvador Amezquita-Pérez[3],
Erika Santiago-González[3],